Pliant Therapeutics, Inc. – NASDAQ:PLRX

Add to watchlist

$1.5

-12.06

-88.94%

Market closed

Open in 3 days

+6.35%

month

+6.35%

quarter

-29.19%

year

Market Cap	777.10M
Enterprise value	1.09B

P/E	-8.62
EV/Sales	112.55
EV/EBITDA	-9.33
Price/Sales	114.39
Price/Book	3.53
PEG ratio	1.01
EPS	-2.87

Revenue	N/A
EBITDA	-186.53M
Income	-170.74M
Revenue Q/Q	-100%
Revenue Y/Y	-47.91%

Profit margin	-1273.32%
Oper. margin	-1313.37%
Gross margin	51.51%
EBIT margin	-1313.37%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Profit margin
Jun 2023	248K	-41.19M	-16609.68%
Sep 2023	0	-41.48M
Dec 2023	4.83M	-41.10M	-849.36%
Mar 2024	0	-46.95M

Pliant Therapeutics Financials Estimate

Q Y

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Analyst Estimates
Mar 2024	0	-46.95M
Sep 2025	500K	-54.21M	-10842.71%
Oct 2025	500K	-56.36M	-11273.93%
Dec 2025	500K	-59.17M	-11835.54%

Analysts Price target
Financials & Ratios estimates

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Debt to assets
Jun 2023	574891000	41.82M	7.28%
Sep 2023	540464000	37.41M	6.92%
Dec 2023	512154000	38.57M	7.53%
Mar 2024	521605000	84.27M	16.16%

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Cash Flow
Jun 2023	-24.75M	-22.97M	161K
Sep 2023	-36.22M	38.25M	699K
Dec 2023	-25.10M	31.92M	219K
Mar 2024	-30.27M	59.54M	21.78M

Pliant Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Pliant Therapeutics
Employees

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Employee count
Aug 2023	136
Sep 2023	155
Oct 2023	155
Nov 2023	155
Dec 2023	159
Jan 2024	159
Feb 2024	159
Mar 2024	158
Apr 2024	158
May 2024	158
Jun 2024	158
Jul 2024	158

Pliant Therapeutics
Hedge Funds Holdings Q1 2023

51.63% -43.89%

of PLRX is owned by hedge funds

76 -49

hedge funds hold PLRX stock

21.69M -23.01M

shares is hold by hedge funds

PLRX hedge funds holdings changes

Pliant Therapeutics
Insider Trading

Pliant Therapeutics, Inc. (NASDAQ:PLRX): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	0	34919
Jan 2024	0	60780
Jul 2024	0	79496

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	10 Jul 2024	LEFEBVRE ERIC officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	12,319	$11.56	$142,408
Sale	10 Jul 2024	HULL HANS officer: Chief Business Officer officer: Chief Business Officer	Common Stock	9,900	$11.56	$114,444
Sale	10 Jul 2024	CUMMINGS KEITH LAMONT officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	10,911	$11.56	$126,131
Sale	10 Jul 2024	COULIE BERNARD director, officer: President and CEO director, officer: President an..	Common Stock	38,710	$11.56	$447,488
Sale	10 Jul 2024	OUIMETTE MIKE officer: General Counsel & Corp. Sec'y officer: General Counsel & Corp..	Common Stock	7,656	$11.56	$88,503
Option	2 May 2024	CUMMINGS KEITH LAMONT officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	21,000	$2.08	$43,680
Option	2 May 2024	CUMMINGS KEITH LAMONT officer: Chief Financial Officer officer: Chief Financial Officer	Stock Option (Right to Buy)	21,000	$2.08	$43,680
Sale	17 Jan 2024	CUMMINGS KEITH LAMONT officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	9,781	$17.23	$168,527
Sale	17 Jan 2024	HULL HANS officer: Chief Business Officer officer: Chief Business Officer	Common Stock	9,786	$17.23	$168,613
Sale	17 Jan 2024	COULIE BERNARD director, officer: President and CEO director, officer: President an..	Common Stock	25,721	$17.23	$443,173

PLRX insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Amino acid compounds with unbranched linkers and methods of use Filling date: 27 Jun 2019 Issue date: 26 Jul 2022	27 Jun 2019	26 Jul 2022
Application	Application INTEGRIN INHIBITOR AND USES THEREOF Filling date: 19 Nov 2021 Issue date: 9 Jun 2022	19 Nov 2021	9 Jun 2022
Application	Application AMINO ACID COMPOUNDS AND METHODS OF USE Filling date: 18 Oct 2021 Issue date: 12 May 2022	18 Oct 2021	12 May 2022
Grant	Grant Utility: Substituted amino acids as integrin inhibitors Filling date: 8 Oct 2019 Issue date: 23 Nov 2021	8 Oct 2019	23 Nov 2021
Application	Application COMPOSITIONS AND METHODS FOR ACTIVATION OF INTEGRINS Filling date: 13 Nov 2020 Issue date: 20 May 2021	13 Nov 2020	20 May 2021
Application	Application AMINO ACID COMPOUNDS AND METHODS OF USE Filling date: 5 Jun 2020 Issue date: 29 Apr 2021	5 Jun 2020	29 Apr 2021
Application	Application N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE Filling date: 4 Mar 2020 Issue date: 28 Jan 2021	4 Mar 2020	28 Jan 2021
Application	Application AMINO ACID COMPOUNDS AND METHODS OF USE Filling date: 26 Jun 2020 Issue date: 21 Jan 2021	26 Jun 2020	21 Jan 2021
Application	Application DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS Filling date: 8 Apr 2020 Issue date: 12 Nov 2020	8 Apr 2020	12 Nov 2020
Grant	Grant Utility: Amino acid compounds and methods of use Filling date: 7 Mar 2019 Issue date: 6 Oct 2020	7 Mar 2019	6 Oct 2020

Pliant Therapeutics
Executives

Insider	Age	Compensation
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. (1966) Pres, Chief Executive Officer & Director	59	$895,270
Dr. Éric Lefebvre M.D. (1964) Chief Medical Officer	61	$646,040
Mr. Johannes P. Hull (1975) Chief Bus. Officer	50	$560,840

Pliant Therapeutics
Latest News

Monday, 18 November 2024
18:00	Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024	globenewswire.com
Monday, 24 June 2024
12:56	7 Biotech Stocks to Buy on the Dip: June 2024	investorplace.com
Thursday, 13 June 2024
16:05	Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors	globenewswire.com
Wednesday, 12 June 2024
16:05	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 6 June 2024
08:00	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™	globenewswire.com
Tuesday, 21 May 2024
18:50	Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference	globenewswire.com
Tuesday, 14 May 2024
07:30	Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis	globenewswire.com
Tuesday, 7 May 2024
08:00	Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™	globenewswire.com
Monday, 6 May 2024
16:05	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	globenewswire.com
Wednesday, 1 May 2024
08:00	Pliant Therapeutics to Participate in Upcoming Investor Events	globenewswire.com
Tuesday, 2 April 2024
08:00	Pliant Therapeutics to Participate in Upcoming Investor Events	globenewswire.com
Wednesday, 27 March 2024
10:23	Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	globenewswire.com
Tuesday, 12 March 2024
07:30	Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	globenewswire.com
Thursday, 7 March 2024
11:01	Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline	Zacks Investment Research
Thursday, 9 November 2023
09:47	Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?	Zacks Investment Research
Wednesday, 27 September 2023
12:02	Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study	Zacks Investment Research
Tuesday, 26 September 2023
12:10	Why Shares of Pliant Therapeutics Are Rising Tuesday	The Motley Fool
08:09	Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial	Market Watch
Monday, 25 September 2023
16:05	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis	GlobeNewsWire
Friday, 11 August 2023
12:19	Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled	Seeking Alpha
Wednesday, 9 August 2023
18:59	Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates	Zacks Investment Research
Tuesday, 25 July 2023
08:00	Pliant Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 9 May 2023
19:06	Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Saturday, 15 April 2023
07:55	Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market	Seeking Alpha
Sunday, 9 April 2023
13:19	7 Biotech Stocks to Buy for 100% Returns	InvestorPlace
Thursday, 9 March 2023
19:49	Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 3 March 2023
10:48	Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis	Seeking Alpha
Thursday, 26 January 2023
16:16	Why Pliant Therapeutics Stock Is Skyrocketing This Week	The Motley Fool
04:23	Pliant Therapeutics Gaps 34% Higher: More Upside To Come?	MarketBeat
Wednesday, 25 January 2023
12:02	Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Jul 2025

From Nebius Group To EOS: A Strong Year And What's Next For Our Family Office
Seeking Alpha 26 Sep 2023

Pliant Therapeutics' Multi-Pronged Fibrosis Play
Seeking Alpha 11 Aug 2023

Pliant Therapeutics: Promising Phase 2a Bexotegrast Data Unveiled
Seeking Alpha 23 May 2023

Pliant Therapeutics: Trading In Oversold Territory, Buying The Dip
Seeking Alpha 18 Apr 2023

Galecto: Promising Pipeline And Excellent Risk-Reward
Seeking Alpha 15 Apr 2023

Pliant Therapeutics: A Breath Of Fresh Air For A Multibillion Dollar IPF Market
Seeking Alpha 15 Mar 2023

Pliant Therapeutics: Latest Financials Support Stable Investment In Future Growth
Seeking Alpha 3 Mar 2023

Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis
Seeking Alpha 16 Dec 2022

Pliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC
Seeking Alpha 20 Aug 2022

Pliant Therapeutics: Wait For A Better Price To Get In

Frequently Asked Questions (FAQ)

What's the price of Pliant Therapeutics stock today?

One share of Pliant Therapeutics stock can currently be purchased for approximately $1.5.
When is Pliant Therapeutics's next earnings date?

Unfortunately, Pliant Therapeutics's (PLRX) next earnings date is currently unknown.
Does Pliant Therapeutics pay dividends?

No, Pliant Therapeutics does not pay dividends.
How much money does Pliant Therapeutics make?

Pliant Therapeutics has a market capitalization of 777.10M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 83.69% to 1.58M US dollars.
What is Pliant Therapeutics's stock symbol?

Pliant Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "PLRX".
What is Pliant Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Pliant Therapeutics?

Shares of Pliant Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Pliant Therapeutics's key executives?
Pliant Therapeutics's management team includes the following people:
- Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $895,270)
- Dr. Éric Lefebvre M.D. Chief Medical Officer(age: 61, pay: $646,040)
- Mr. Johannes P. Hull Chief Bus. Officer(age: 50, pay: $560,840)
How many employees does Pliant Therapeutics have?

As Jul 2024, Pliant Therapeutics employs 158 workers.
When Pliant Therapeutics went public?

Pliant Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 3 Jun 2020.
What is Pliant Therapeutics's official website?

The official website for Pliant Therapeutics is pliantrx.com.
Where are Pliant Therapeutics's headquarters?

Pliant Therapeutics is headquartered at 260 Littlefield Avenue, South San Francisco, CA.
How can i contact Pliant Therapeutics?

Pliant Therapeutics's mailing address is 260 Littlefield Avenue, South San Francisco, CA and company can be reached via phone at +65 04816770.

Pliant Therapeutics, Inc.

pliantrx.com

Exchange:

NASDAQ

Full time employees:

166

Industry:

Biotechnology

Sector:

Healthcare

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

+65 04816770

260 Littlefield Avenue
South San Francisco, CA 94080

CIK: 0001746473
ISIN: US7291391057
CUSIP: 729139105